These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2188898)

  • 1. Biological activity of nasally administered insulin in normal subjects.
    Nolte MS; Taboga C; Salamon E; Moses A; Longenecker J; Flier J; Karam JH
    Horm Metab Res; 1990 Mar; 22(3):170-4. PubMed ID: 2188898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
    Steiner S; Pfützner A; Wilson BR; Harzer O; Heinemann L; Rave K
    Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):17-21. PubMed ID: 11835120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
    Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ
    Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action profile of biosynthetic human proinsulin trials with the BIOSTATOR in metabolically normal subjects.
    Bottermann P; Wahl K; Ermler R; Gray IP; Hales CN
    Horm Metab Res Suppl; 1988; 18():6-11. PubMed ID: 3056813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semisynthetic human insulin: pharmacokinetics and biological potency in healthy subjects in comparison with highly purified porcine insulin.
    Schulz B; Stöwhas H; Becker R; Steinicke A; Besch W
    Exp Clin Endocrinol; 1988 Mar; 92(3):307-13. PubMed ID: 3075554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles.
    Rave K; Nosek L; Heinemann L; Gonzales C; Ernest CS; Chien J; Muchmore D
    Diabet Med; 2004 Jul; 21(7):763-8. PubMed ID: 15209771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia.
    Cersosimo E; Pisters PW; Pesola G; Rogatko A; Vydelingum NA; Bajorunas D; Brennan MF
    Surgery; 1991 Apr; 109(4):459-67. PubMed ID: 2008651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of mixing regular- and intermediate-acting insulins on their absorption and biological activity.
    Schulz B; Menzel R; Besch W
    Exp Clin Endocrinol; 1988 Mar; 91(1):27-34. PubMed ID: 3286272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique.
    Becker RH; Frick AD; Burger F; Scholtz H; Potgieter JH
    Exp Clin Endocrinol Diabetes; 2005 May; 113(5):292-7. PubMed ID: 15926116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
    Heinemann L; Weyer C; Rave K; Stiefelhagen O; Rauhaus M; Heise T
    Exp Clin Endocrinol Diabetes; 1997; 105(3):140-4. PubMed ID: 9228509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equipotency of insulin glargine and regular human insulin on glucose disposal in healthy subjects following intravenous infusion.
    Scholtz HE; Pretorius SG; Wessels DH; Venter C; Potgieter MA; Becker RH
    Acta Diabetol; 2003 Dec; 40(4):156-62. PubMed ID: 14740274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects.
    Westerbacka J; Bergholm R; Tiikkainen M; Yki-Järvinen H
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):320-4. PubMed ID: 14656737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics.
    de la Peña A; Seger M; Rave K; Heinemann L; Silverman B; Muchmore DB
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S75-80. PubMed ID: 19772452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
    Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ
    Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.